Neoadjuvant docetaxel in high-risk prostate cancer

JRCT ID: jRCTs021180009

Registered date:25/03/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: prostate cancer
• Date of first enrollment: 30/09/2015
• Target sample size: 150
• Study type: Interventional
• Intervention(s): Neoadjuvant treatment with androgen deprivation therapy, docetaxel and estramustine phosphate followed by radical prostatectomuy

Outcome(s)

• Primary Outcome: surgical CR rate
• Secondary Outcome: biochemical recurrence, cancer specific survival, overall survival, adverse event

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: <= 70age old
• Gender: Male
• Include criteria: pathologically diagnosed high-risk prostate cancer who have a plan to receive surgical treatment
• Exclude criteria: .Inappropriate patients for this study judged by the physicians

Related Information

• Primary Sponsor: Narita Shintaro